Koichi Ogura1,2, Tomohiro Fujiwara1,3, John H Healey1,4. 1. Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan. 3. Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama City, Japan. 4. Weill Cornell Medical College, New York, New York, USA.
Abstract
AIMS: Time to treatment initiation (TTI) is generally defined as the time from the histological diagnosis of malignancy to the initiation of first definitive treatment. There is no consensus on the impact of TTI on the overall survival in patients with a soft-tissue sarcoma. The purpose of this study was to determine if an increased TTI is associated with overall survival in patients with a soft-tissue sarcoma, and to identify the factors associated with a prolonged TTI. METHODS: We identified 23,786 patients from the National Cancer Database who had undergone definitive surgery between 2004 and 2015 for a localized high-grade soft-tissue sarcoma of the limbs or trunk. A Cox proportional hazards model was used to examine the relationship between a number of factors and overall survival. We calculated the incidence rate ratio (IRR) using negative binomial regression models to identify the factors that affected TTI. RESULTS: Patients in whom the time to treatment initiation was prolonged had poorer overall survival than those with a TTI of 0 to 30 days. These were: 31 to 60 days (hazard ratio (HR) 1.08, p = 0.011); 61 to 90 days (HR 1.11, p = 0.044); and 91 days (HR 1.22; p = 0.003). The restricted cubic spline showed that the hazard ratio increased substantially with a TTI longer than 50 days. Non-academic centres (vs academic centres; IRR ranging from 0.64 to 0.86; p < 0.001) had a shorter TTI. Those insured by Medicaid (vs private insurance; IRR 1.34), were uninsured (vs private insurance; IRR 1.17), or underwent a transition in care (IRR 1.62) had a longer TTI. CONCLUSION: A time to treatment initiation of more than 30 days after diagnosis was independently associated with poorer survival. The hazard ratio showed linear increase, especially if the TTI was more than 50 days. We recommend starting treatment within 30 days of diagnosis to achieve the highest likelihood of cure for localized high-grade soft-tissue sarcomas in the limbs and trunk, even when a patient needs to be referred to a specialist centre. Cite this article: Bone Joint J 2021;103-B(6):1142-1149.
AIMS: Time to treatment initiation (TTI) is generally defined as the time from the histological diagnosis of malignancy to the initiation of first definitive treatment. There is no consensus on the impact of TTI on the overall survival in patients with a soft-tissue sarcoma. The purpose of this study was to determine if an increased TTI is associated with overall survival in patients with a soft-tissue sarcoma, and to identify the factors associated with a prolonged TTI. METHODS: We identified 23,786 patients from the National Cancer Database who had undergone definitive surgery between 2004 and 2015 for a localized high-grade soft-tissue sarcoma of the limbs or trunk. A Cox proportional hazards model was used to examine the relationship between a number of factors and overall survival. We calculated the incidence rate ratio (IRR) using negative binomial regression models to identify the factors that affected TTI. RESULTS: Patients in whom the time to treatment initiation was prolonged had poorer overall survival than those with a TTI of 0 to 30 days. These were: 31 to 60 days (hazard ratio (HR) 1.08, p = 0.011); 61 to 90 days (HR 1.11, p = 0.044); and 91 days (HR 1.22; p = 0.003). The restricted cubic spline showed that the hazard ratio increased substantially with a TTI longer than 50 days. Non-academic centres (vs academic centres; IRR ranging from 0.64 to 0.86; p < 0.001) had a shorter TTI. Those insured by Medicaid (vs private insurance; IRR 1.34), were uninsured (vs private insurance; IRR 1.17), or underwent a transition in care (IRR 1.62) had a longer TTI. CONCLUSION: A time to treatment initiation of more than 30 days after diagnosis was independently associated with poorer survival. The hazard ratio showed linear increase, especially if the TTI was more than 50 days. We recommend starting treatment within 30 days of diagnosis to achieve the highest likelihood of cure for localized high-grade soft-tissue sarcomas in the limbs and trunk, even when a patient needs to be referred to a specialist centre. Cite this article: Bone Joint J 2021;103-B(6):1142-1149.
Entities:
Keywords:
National Cancer Database; Overall survival; Soft-tissue sarcoma; Time to treatment initiation (TTI)
Authors: Samuel U Takvorian; Arman Oganisian; Ronac Mamtani; Nandita Mitra; Lawrence N Shulman; Justin E Bekelman; Rachel M Werner Journal: JAMA Netw Open Date: 2020-02-05
Authors: Gannon L Curtis; Joshua M Lawrenz; Jaiben George; Joe F Styron; Jacob Scott; Chirag Shah; Dale R Shepard; Brian Rubin; Lukas M Nystrom; Nathan W Mesko Journal: J Surg Oncol Date: 2018-06-27 Impact factor: 3.454
Authors: Pamela Samson; Aalok Patel; Tasha Garrett; Traves Crabtree; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-04-16 Impact factor: 4.330
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Neal S Topham; Brian L Egleston Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Colin T Murphy; Thomas J Galloway; Elizabeth A Handorf; Lora Wang; Ranee Mehra; Douglas B Flieder; John A Ridge Journal: Cancer Date: 2014-12-09 Impact factor: 6.860
Authors: Joseph Featherall; Gannon L Curtis; Joshua M Lawrenz; Yuxuan Jin; Jaiben George; Jacob Scott; Chirag Shah; Dale Shepard; Brian P Rubin; Lukas M Nystrom; Nathan W Mesko Journal: J Surg Oncol Date: 2019-10-06 Impact factor: 3.454
Authors: Alok A Khorana; Katherine Tullio; Paul Elson; Nathan A Pennell; Stephen R Grobmyer; Matthew F Kalady; Daniel Raymond; Jame Abraham; Eric A Klein; R Matthew Walsh; Emily E Monteleone; Wei Wei; Brian Hobbs; Brian J Bolwell Journal: PLoS One Date: 2019-03-01 Impact factor: 3.240